Objective: To investigate the influence of intravenous immunoglobulin (IVIG) timing of medication on children with Kawasaki disease. Methods: A total of 52 cases of Kawasaki disease were selected in our hospital during the period from January 2011 to June 2017. According to the IVIG timing of medication, all the cases were divided into early treatment group (diagnosed within 7 days) and late treatment group (more than 7 days of diagnosis and treatment); 19 cases in early treatment group and 33 cases in the late treatment group. The therapeutic effects and complications were collected and compared. Results: Heat fading time, lymph node enlargement time, mucosal hyperemia time and rash duration time were (5.75±0.52), (6.51±0.68), (4.60±0.21) and (5.62±0.32) d in early treatment group respectively, (10.21±0.66), (8.65±0.64), (8.95±0.38) and (8.14±0.68) d in late treatment group, respectively, and there are significant difference in the these indexes (P<0.05). The rate of coronary dilatation in the early treatment group was 5.26%, which was lower than that of the late treatment group (18.18%), and the difference was statistically significant (P<0.05). The results showed that the indexes of WBC, PLT, CRP and ESR in the early treatment group were better than those in the late treatment group (P<0.05). Before treatment, there was no significant difference in aspartate aminotransferase (AST), creatine kinase (CK) and creatine kinase isozyme (CK-MB) between the two groups (P>0.05). After treatment, the above indexes of the two groups were obviously reduced, and the indexes of early treatment group were significantly lower than late treatment group (P<0.05). Conclusion: The early treatment Kawasaki disease with IVIG can reduce coronary complications and improve the symptoms and blood index.